CN1858060B - 固相多肽合成依非巴特的制备方法 - Google Patents
固相多肽合成依非巴特的制备方法 Download PDFInfo
- Publication number
- CN1858060B CN1858060B CN2005100256837A CN200510025683A CN1858060B CN 1858060 B CN1858060 B CN 1858060B CN 2005100256837 A CN2005100256837 A CN 2005100256837A CN 200510025683 A CN200510025683 A CN 200510025683A CN 1858060 B CN1858060 B CN 1858060B
- Authority
- CN
- China
- Prior art keywords
- resin
- fmoc
- nitrogen dries
- dmf
- cys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 34
- 108010056764 Eptifibatide Proteins 0.000 title claims abstract description 32
- 229960004468 eptifibatide Drugs 0.000 title claims abstract description 10
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 6
- 239000007790 solid phase Substances 0.000 title claims abstract description 6
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000011347 resin Substances 0.000 claims abstract description 119
- 229920005989 resin Polymers 0.000 claims abstract description 119
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 17
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 230000003647 oxidation Effects 0.000 claims abstract description 8
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000005520 cutting process Methods 0.000 claims abstract description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims abstract description 5
- 239000000178 monomer Substances 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 208
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 186
- 229910052757 nitrogen Inorganic materials 0.000 claims description 93
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 92
- 238000005406 washing Methods 0.000 claims description 44
- 238000006243 chemical reaction Methods 0.000 claims description 30
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 claims description 28
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 28
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 28
- 239000012317 TBTU Substances 0.000 claims description 27
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 27
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 claims description 27
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 22
- 229940056984 integrilin Drugs 0.000 claims description 21
- 239000012043 crude product Substances 0.000 claims description 15
- -1 S-benzyl thiohydracrylic acid Chemical compound 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 8
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 238000007664 blowing Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 5
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 claims description 4
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 claims description 4
- MGHMWKZOLAAOTD-DEOSSOPVSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1h-indol-3-yl)propanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 MGHMWKZOLAAOTD-DEOSSOPVSA-N 0.000 claims description 4
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 claims description 4
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000008961 swelling Effects 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 238000002203 pretreatment Methods 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 abstract description 8
- 150000001408 amides Chemical class 0.000 abstract description 5
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- QKHQITUHYKZKJI-UHFFFAOYSA-N 2-benzylsulfanylpropanoic acid Chemical compound OC(=O)C(C)SCC1=CC=CC=C1 QKHQITUHYKZKJI-UHFFFAOYSA-N 0.000 abstract 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000011084 recovery Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000015795 Platelet Membrane Glycoproteins Human genes 0.000 description 1
- 108010010336 Platelet Membrane Glycoproteins Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000005524 benzylchlorides Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100256837A CN1858060B (zh) | 2005-05-08 | 2005-05-08 | 固相多肽合成依非巴特的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100256837A CN1858060B (zh) | 2005-05-08 | 2005-05-08 | 固相多肽合成依非巴特的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1858060A CN1858060A (zh) | 2006-11-08 |
CN1858060B true CN1858060B (zh) | 2010-09-29 |
Family
ID=37297020
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100256837A Active CN1858060B (zh) | 2005-05-08 | 2005-05-08 | 固相多肽合成依非巴特的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1858060B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013117083A1 (zh) * | 2012-02-06 | 2013-08-15 | 成都圣诺科技发展有限公司 | 一种依非巴特的制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101314612B (zh) * | 2008-05-08 | 2011-07-20 | 吉尔生化(上海)有限公司 | 固相多肽合成海沙瑞林的方法 |
WO2009150657A1 (en) * | 2008-06-09 | 2009-12-17 | Natco Pharma Limited | Improved process for preparation of eptifibatide by fmoc solid phase synthesis |
CN101538314B (zh) * | 2009-01-13 | 2012-10-03 | 深圳翰宇药业股份有限公司 | 一种纯化爱啡肽的方法 |
CN101838308B (zh) * | 2009-03-17 | 2012-06-27 | 无锡市凯利药业有限公司 | 依替巴肽的固相合成方法 |
CN101792487A (zh) * | 2010-03-25 | 2010-08-04 | 西北工业大学 | 一种固相环化合成Laterocidin化合物的方法 |
CN101967179B (zh) * | 2010-09-02 | 2013-05-29 | 周又佳 | 一种将含巯基肽从树脂上切落的试剂及切落方法 |
CN104610426A (zh) * | 2015-01-07 | 2015-05-13 | 哈尔滨吉象隆生物技术有限公司 | 一种依替巴肽线性肽树脂裂解的方法 |
CN117024513A (zh) * | 2023-07-20 | 2023-11-10 | 杭州信海医药科技有限公司 | 一种依替巴肽的合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003093302A2 (en) * | 2002-05-03 | 2003-11-13 | Avecia Limited | Process for the synthesis of peptides amides by side-chain attachement to a solid phase |
CN1500805A (zh) * | 2002-11-14 | 2004-06-02 | 吉尔生化(上海)有限公司 | 一种制备依非巴特的新工艺 |
CN1552728A (zh) * | 2003-05-29 | 2004-12-08 | 上海子能药物研究有限公司 | 一种生长抑素的合成方法 |
CN1563076A (zh) * | 2004-04-02 | 2005-01-12 | 西南生物工程产业化中试基地有限公司 | 一种用于治疗性功能障碍的α-MSH类似物及制备方法 |
-
2005
- 2005-05-08 CN CN2005100256837A patent/CN1858060B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003093302A2 (en) * | 2002-05-03 | 2003-11-13 | Avecia Limited | Process for the synthesis of peptides amides by side-chain attachement to a solid phase |
CN1500805A (zh) * | 2002-11-14 | 2004-06-02 | 吉尔生化(上海)有限公司 | 一种制备依非巴特的新工艺 |
CN1552728A (zh) * | 2003-05-29 | 2004-12-08 | 上海子能药物研究有限公司 | 一种生长抑素的合成方法 |
CN1563076A (zh) * | 2004-04-02 | 2005-01-12 | 西南生物工程产业化中试基地有限公司 | 一种用于治疗性功能障碍的α-MSH类似物及制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013117083A1 (zh) * | 2012-02-06 | 2013-08-15 | 成都圣诺科技发展有限公司 | 一种依非巴特的制备方法 |
US9394341B2 (en) | 2012-02-06 | 2016-07-19 | Chengdu Shengnuo Biotec Co., Ltd. | Eptifibatide preparation method |
Also Published As
Publication number | Publication date |
---|---|
CN1858060A (zh) | 2006-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1858060B (zh) | 固相多肽合成依非巴特的制备方法 | |
CN101412752B (zh) | 齐考诺肽的固相合成方法 | |
CN101475631B (zh) | 比伐卢定的液相合成方法 | |
CN101357937B (zh) | 固相多肽合成阿托西般的制备方法 | |
CN101104638B (zh) | 胸腺素α1的固相合成工艺 | |
CN1990501B (zh) | 固相多肽合成缩宫素的制备方法 | |
CN110684077A (zh) | 一种阿基瑞林的规模化合成方法 | |
CN105017387A (zh) | 一种制备利那洛肽的方法 | |
CN1923849B (zh) | 固相多肽合成奥曲肽的制备方法 | |
CN103012563A (zh) | 抗菌肽依色格南的固相合成方法 | |
CN109734778A (zh) | 一种维拉卡肽的制备方法 | |
CN111748019A (zh) | 一种多肽衍生化合物的合成方法 | |
CN110128505A (zh) | 一种戈舍瑞林杂质的合成方法 | |
CN110054662B (zh) | 一种固相合成Etelcalcetide的方法 | |
CN101838308B (zh) | 依替巴肽的固相合成方法 | |
CN1865283B (zh) | 固相多肽合成鲑鱼降钙素的制备方法 | |
CN101857629A (zh) | 布雷默浪丹的固相合成方法 | |
CN111732649A (zh) | 连续流固相反应制备利拉鲁肽 | |
CN1865282B (zh) | 固相多肽合成特利加压素的制备方法 | |
CN103351426B (zh) | 一种醋酸奥曲肽的多肽合成方法 | |
CN1865279B (zh) | 固相多肽合成胸腺五肽的制备方法 | |
CN101085809B (zh) | 巴替非班及其类似物的合成与制备工艺 | |
CN102952175A (zh) | 固相多肽合成生长抑素的方法 | |
CN105111301B (zh) | 一种鲑鱼降钙素的制备方法 | |
EP1756141A1 (en) | Process for the preparation of peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI SOHO-YIMING PHARMACEUTICALS CO., LTD. Free format text: FORMER OWNER: ZHOU DAMING Effective date: 20110901 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 200070 ZHABEI, SHANGHAI TO: 200333 PUTUO, SHANGHAI |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110901 Address after: 200333 Qianyang Road, Shanghai, No. 57, No. Patentee after: Shanghai Soho-yiming Pharmaceuticals Co., Ltd. Address before: 1401 room 1, No. 688, Lane 200070, Gonghe Road, Shanghai Patentee before: Zhou Daming |